Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing.
François M, Copland IB, Yuan S, Romieu-Mourez R, Waller EK, Galipeau J. · 2012
Read Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing. by François M, Copland IB, Yuan S, Romieu-Mourez R, Waller EK, Galipeau J. (2012) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3279133.txt.
Introduction
Moïra François and colleagues discovered why frozen stem cells underperform in immune therapy, in this 2012 paper in Cytotherapy. Mesenchymal stromal cells can calm T cells, yet clinical results were inconsistent, and a major trial in graft-versus-host disease had failed. The team suspected the problem lay in the cells themselves: trials infuse banked cells straight from the freezer, while laboratory studies use cells in active growth.
Freshly thawed cells from healthy donors switched on heat-shock proteins. They failed to respond to the licensing signal interferon-gamma by making the suppressive enzyme IDO. They were also poor at restraining T cell proliferation. A single day of culture after thawing fully restored their responsiveness and suppressive power. The authors argue this thaw-and-infuse practice may explain the disappointing trial results, and that a short recovery culture could fix it.
Catalog record
| CREATOR | François M, Copland IB, Yuan S, Romieu-Mourez R, Waller EK, Galipeau J. |
|---|---|
| YEAR | 2012 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing By Moïra François, Ian B Copland, Shala Yuan, Raphaëlle Romieu-Mourez, Edmund K Waller, Jacques Galipeau Published in: Cytotherapy DOI: 10.3109/14653249.2011.623691 ABSTRACT Abstract Human mesenchymal stromal cells (MSC) can suppress T-cell activation in vitro in an indoleamine 2,3-dioxygenase (IDO)-dependent manner. However, their clinical effects on immune ailments have been inconsistent, with a recent phase III study showing no benefit in acute graft-versus-host disease (GvHD). We here tested the hypothesis that the banked, cryopreserved MSC often used in clinical trials display biologic properties distinct from that of MSC in the log phase of growth typically examined in pre-clinical studies. In freshly thawed cryopreserved MSC derived from normal human volunteers, we observed that MSC up-regulate heat-shock proteins, are refractory to interferon (IFN)-γ-induced up-regulation of IDO, and are compromised in suppressing CD3/CD28-driven T cell proliferation. Immune suppressor activity, IFN-γ responsiveness and induction of IDO were fully restored following 24 h of MSC tissue culture post-thaw. These results highlight a possible cause for the inefficacy of MSC-based immunotherapy reported in clinical trials using cryopreserved MSC thawed immediately prior to infusion. Keywords: cryopreservation; immunosuppression; immunotherapy; indoleamine 2,3-dioxygenase; interferon-gamma; mesenchymal stromal cells INTRODUCTION One mechanism by which human bone marrow-derived mesenchymal stromal cells (MSC) suppress T-cell proliferation in vitro is mediated by the induction of indoleamine 2,3-dioxygenase (IDO) (1,2). Because of their ability to inhibit activated T cells specifically, MSC have been the subject of phase I/II trials for their potential use as a cell-based immunotherapeutic for the treatment of autoimmune and alloimmune disorders (3-6). Clinical studies have demonstrated that the administration of autologous or allogeneic MSC is safe, and numerous phase II studies have suggested encouraging potency, particularly in the treatment of steroid-resistant graft-versus-host disease (GvHD) (7). However, therapeutic effectiveness of MSC is not universally observed (6), including the results of a large phase III trial of major histocompatibility complex (MHC)-unmatched allogeneic MSC for GvHD recently completed in the USA (8). The current model for MSC-based immunotherapy is to expand cells ex vivo, cryogenically bank them until needed, then administer thawed MSC intravenously to the patient. Until now, the effect of cryopreservation recovery on the immunosuppressive properties of MSC has not been investigated. With the present study, we demonstrate that freshly thawed MSC are unable to suppress T-cell proliferation in vitro, which correlates with impaired up-regulation of IDO in response to interferon (IFN)-γ. These observations provide some insight on the inconsistencies between the pre-clinical and clinical utility of MSC for treatment of immune ailments. METHODS Cells Human MSC were isolated and cultured as described elsewhere (9). After the third passage, the MSC cultures were assayed by flow cytometry analysis for the absence of CD45+ and CD31 + contaminating cells and expression of CD44, CD73, CD90 and CD 105 (BD Biosdence, Mississauga, ON, Canada), and subjected to a differentiation assay toward adipocyte and osteocyte lineages, as described elsewhere (10). Human peripheral blood mononuclear cells (PBMC) were isolated from leukapheresis obtained from healthy volunteers using a Ficoll density gradient. Cell viability Frozen MSC were thawed, washed in media and cultured for 4 h, 24 h or 7 days before all cells, floating and adherent, were analyzed using an annexin V and propidium iodide (PI) staining kit (Invitrogen, Burlington, ON, Canada) and quantified by flow cytometry. Trypan blue exclusion staining was also carried out in parallel, and a consistently greater ‘viability’ assessment was observed compared with annexinV/PI staining (trypan blue viability >80%, annexinV/PI viability ≤ 60%, immediately after thawing). We believe this is due to the fact that trypan blue staining only shows dead cells and does not include dying cells; therefore trypan blue values were disregarded. T cell proliferation assay Carboxyfluorescein succinimidyl ester (CFSE; Invitrogen)-labeled PBMC were cultured at 400 000 cells/well in a 24-well plate with cultured, freshly thawed or paraformaldehyde (PFA)-fixed MSC at a ratio of MSC:PBMC of 1:3 and 1:9. T lymphocytes were stimulated using 0.4 μg/mL anti-human CD3 and CD28 antibodies (clone HIT3a and CD28.2, respectively, from BD Pharmagen, Mississauga, ON, Canada). T-cell proliferation was determined 4 days later by flow cytometry analysis of CFSE fluorescence intensity. Western blot Anti-human IDO (GenScript, Piscataway, NJ, USA) and anti-human phospho-STAT-1 (clone 58D6; Cell Signaling, Pickering, ON, Canada) -specific antibodies were used to detect protein expression on whole cell protein extracts isolated from MSC by immunoblot analysis. Where indicated, MSC were activated with recombinant human IFN-γ (5 ng/mL; R&D System, Burlington, ON, Canada). Real-time quantitative polymerase chain reaction DNA-free total RNA was extracted and reverse transcribed as described elsewhere (10). Real-time quantitative polymerase chain reaction (qPCR) assays were performed in duplicate on an ABI 7500 fast real-time PCR system thermal cycler and SYBR green mastermix (Applied Biosystems, Carlsbad, CA, USA) with human primer sequences (5'3’ forward, reverse) for: IDO, GCCCTTCAAGTGTTTCACCAA, CCAGCC AGACAAATATATGCGA; Chemokine (C-C motif) ligand 2 (CCL2), CAAGCAGAAGTGGGTTCAG-GAT, TCTTCGGAGTTTGGGTTTGC; interleukin (IL-6), ATGAAGTTCCTCTCTGCAAGAGACT, CACTAGGTTTGCCGAGTAGATCTQheatshock protein (Hsp27), CTGGCGCGTGTCCCTGGATG, GCTAGCTTGGGCATGGGGGC; Hsp47, CTGC TAGTCAACGCCATGTTCTTC, TCTGTGTCCA ACTCAAAGGQ Hsp56, TCCTCACCCCCGACG-GTGTG, CTGGCTTGTGCTGCCTGGCT; Hsp 70A,GGTCCGGATAACGGCTAGCCT,CCACCG GGTCGCCGAACTTG; Hsp70B, CATGCCCCG ATCTGCCCGAAC, GCACCTTCCCGCCCAGT TGAG; Hsp90, ATGGCTGCTTCCCAGGTGAT GCC, ACCTCAGGCTCATGACACCAGC; 18S ribosomal RNA (18S), TTACCAAAAGTGGCCCA CTA, GAAAGATGGTGAACTATGCC. Primers were designed using the National Center for Biotechnology Information (NCBI)/primer blast designing tool. Data were analyzed using the relative quantification method (11). Statistical analysis Data are reported as mean ± standard deviation (SD). All calculations were carried out using Graph-Pad Prism software (GraphPad Software, La Jolla, CA, USA). Comparisons between groups were made by anova. RESULTS AND DISCUSSION To determine the immunosuppressive potential of cryopreserved MSC toward T-cell activation, we analyzed their potency to suppress PBMC proliferation in comparison with MSC maintained in culture for 7 days. Early passage MSC were frozen in α Minimum Essential Medium (MEM), 30% fetal bovine serum and 5% dimethyl sulfoxide at −80°C for 24 h, then transferred to liquid nitrogen for 1 week before use. Cell viability analysis by flow cytometry using annexin V- and PI-labeling revealed that, in cultured MSC, the percentage of live cells (annexin V− and PI") was 92% and 91% for donors A and B, respectively, while in their thawed counterparts the percentage of live cells dropped to 61% and 44%, respectively (Figure 1A). We next tested post-thaw cell culture restoration of immune suppressor function. Freshly thawed cryopreserved MSC and MSC in the log phase of growth were co-cultured with CFSE-labeled PBMC activated with anti-CD3 and -CD28 antibodies at a MSC:PBMC ratio of 1:3, and T-cell proliferation was measured 4 days later. Cryopreserved MSC had a significantly impaired inhibitory effect on the proliferation of activated T cells in comparison with their cultured counterpart maintained in the log phase of growth (P< 0.0001) (Figure 1B). T-cell hyperproliferation observed in the presence of thawed MSC suggested that dead MSC found in the freshly thawed MSC samples may activate T-cell proliferation. To test this hypothesis, we performed a T-cell proliferation assay in which cultured MSC were mixed at a different ratio with PFA-fixed MSC, which served as dead cells, while the MSC:PBMC ratio remained 1:3 (Figure 1C). Adding increasing amounts of fixed MSC while reducing the amount of live MSC diminished the level of T-cell immunosuppression. Hyper-proliferation of T cells could also be observed at ratios of 1:1, 1:2 and 100% fixed, depending on the MSC